Sur Billig viagra i sverige ce plan, c est une réussite. Depuis, elle Hvad koster cialis danmark s est au contraire partout accentuée. Renouait Buy cialis usa 60 mg des liens qu il savait devoir rompre. Je Achat viagra sans ordonnance pharmacie dois prendre sur moi, avaler ma rage. L Acheter viagra pfizer pas cher avancée de l enquête, mardi 15 avril, à 11 heures. A Strasbourg, Vendo viagra entrega calidad a contrareembolso la démonstration était implacable. On Priligy dapoxetina precio a eu affaire à un juge qui était très déterminé. En Comprar coumadin 5mg fait, et M. Les juges Buy levitra usa with paypal appliquent la loi. Son Viagra pas cher livraison rapide auteure : Felicitas Roher. De toute Ou commander du cialis manière, la mort est là. Hamon, dont Donde puedo comprar priligy colombia le syndicat est minoritaire. Ils Clomid precio farmacia m ont demandé si la même chose pouvait m arriver. Jamais Comprar priligy online andorra elle n avait porté plainte. Il Cuanto vale la viagra en la farmacia faut donc s astreindre à de l exercice. C Priligy original+billig est même pour ça qu il est devenu psychiatre. Mais la loi des hommes est changeante.

CONNECT FrameWorks Workshop: Introduction to Venture Capital

February 26, 2013 @ 8:00 am – 12:00 pm
Sanford-Burnham Medical Research Institute
10905 Road to the Cure
San Diego,CA 92121
Brittney Sabbah858-964-1336E-mail

CONNECT FrameWorks Workshops presents Introduction to Venture Capital
In partnership with Perkins Coie, LLP

Program Overview:
Raising money in today’s environment is no easy task — but it can be done if you focus on the right priorities and avoid common deal-killers. In this half-day workshop, George Colindres and Peter Townshend from Perkins Coie LLP will provide you with an overview of venture capital and actionable advice that will prepare you for raising capital from venture capital funds.

Benefits of Attending:

  • Understanding venture funds and how they operate;
  • An overview of venture capital term sheets and financing terms;
  • Understanding the stages of a venture capital financing; and
  • Learning common terms used in such transactions and what they mean.

Who should attend:

Founders, CEOs and managers who are seeking venture funding, as well as scientists and technology experts considering a business start-up in need of venture financing.

About the Presenters:

George Colindres is senior counsel with the Business practice and Emerging Companies group in Perkins Coie’s San Diego and Los Angeles offices.  For over 13 years George has represented emerging growth companies in the tech and life sciences sectors as outside general counsel, advising them on formation and other corporate governance matters, commercial and licensing agreements, employment and compensation matters, preferred stock and other equity financings, convertible promissory note (bridge) financings, venture debt financings and secured transactions, M&A transactions and public offerings. George has also represented venture capital firms, private equity firms, , real estate funds, strategic investors, angels and angel groups and other investors in connection with fund formation, governance matters, making investments and M&A transactions.  Representative industries include social networking, e-commerce, online advertising, online gaming, software, hardware, telecommunications, medical devices, biotechnology, pharmaceuticals and real estate.

Peter N. Townshend
is a partner with Perkins Coie’s Emerging Companies practice.  He has extensive experience representing emerging growth technology companies and venture capital investors in structuring a wide variety of transactions. His practice includes venture capital, angel and other private equity financings; convertible note and other debt financings; mergers and acquisitions; public offerings; corporate governance; distribution, development, manufacturing, co-marketing, licensing and other commercial transactions; stock option plans and executive compensation; and venture capital and private equity fund formation. Peter has worked in a diverse array of industries including social networking, e-commerce, online advertising, online gaming, software and hardware, telecommunications, medical devices, biotechnology, and pharmaceuticals.

Kim Kamdar joined Domain Associates in 2005 and became a Partner in 2011. Present board memberships include Ariosa Diagnostics, Lithera, Obalon Therapeutics, ROX Medical, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. She was also involved with Corthera until the Company was sold to Novartis in February 2010 and BiPar Sciences until that company was sold to sanofi-aventis in April 2009. Dr. Kamdar serves as an advisory board member to Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine. She is a board member of San Diego’s CONNECT Foundation. Additionally, Dr. Kamdar serves as an Advisory Board Member for Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. From 2003-2004, Dr. Kamdar was a Kauffman Fellow with MPM Capital. Prior to joining MPM, Dr. Kamdar was a Research Director at Novartis. She built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. Dr. Kamdar is the author of ten papers as well as the inventor on seven patents.


Date: February 26, 2013

Time: 8:30 a.m. – 12:00 p.m. (Registration begins 8:00 a.m.)

Location: Sanford – Burnham Institute (formerly SKCC)
10905 Road to the Cure
San Diego, CA 92121

Note: A light breakfast will be provided for participants.

Contact: Brittney Sabbah


Phone: 858-964-1336

Fees: Pre-Registration $45.

At the Door $65.

*Registration will close at 3PM on or before February 25.

Register Here